The
of GnRH agonists in the treatment of endometriosis is well established (Lemay et al., 1984) . Although a variety of theories have been proposed to explain the GnRH agonist suppression of estrogen production, its exact mechanism(s) of action in women has not been fully elucidated. Some of the mechanisms proposed are: 1) suppression of pituitary gonadotrope responsiveness to endogenous GnRH resulting in decreased secretion of gonadotropins (Schriock et al., 1985; West et al., 1987) , 2) alteration in the pituitary LH pulse 
Results
All five patients remained anovulatory during the treatment, with the exception of one patient who ovulated once at 2 weeks after the beginning of the treatment. The serum E2 concentration gradually decreased to approximately the menopausal concentration, less than 30 pg/ml, by the twelfth week of the treatment in all patients (Fig. 1) (Fig. 3) . In particular, pituitary LH release after a single dose of GnRH injection, judged by a net increase in the serum LH concentration, was markedly reduced.
We therefore examined the mechanism(s) of action of buserelin which induces suppression of estrogen production by the ovary. The mode of pituitary LH secretion before and during the treatment was studied by frequent blood sampling. Fig. 4 shows thesizing ability of the patients before and during the treatment was evaluated. During the treatment, the serum E2 concentration in the patients was increased to the same extent in response to hMG administration as before the treatment. Fig. 6 shows individual data for four cases obtained before and at the twelfth week after the beginning of treatment.
Thus, there was no difference between the ovarian response to hMG in a pretreatment cycle and in a treatment cycle, suggesting that the GnRH agonist, buserelin, does not have a direct inhibitory effect on ovarian estrogen biosynthesis in patients with endometriosis.
Discussion
The present study was designed to elucidate the mode of action of GnRH agonists in patients with endometriosis. All five patients included in the present study responded to nasal administration of buserelin, and their serum E2 levels fell to near-castrate levels by the twelfth week of the treatment.
This made it possible to evaluate the proposed mechanisms by which GnRH agonists decrease serum E2 in patients with endometriosis. Previous studies in patients with endometriosis (Schriock et al., 1985) and uterine fibroids (West et al., 1987) showed that the serum immunoreactive gonadotropin concentration declined and was suppressed significantly during treatment period with either nasal or subcutaneous administration of GnRH agonist.
It was also demonstrated that there is a relationship between the degree of estrogen suppression and the serum immunoreactive LH concentration (Schriock et al., 1985; West et al., 1987) . In the present study, however, despite the marked reduction in serum E2 during the treatment, neither immunoreactive LH nor FSH in serum significantly declined below the base level. These data suggest that the inhibitory effect of GnRH agonist on estrogen production in patients with endometriosis cannot be explained on the basis of downregulation of pituitary immunoreactive gonadotropin secretion.
Although either subcutaneous or intranasal administration of buserelin to patients with prostatic cancer markedly suppressed serum testosterone to the near-castrate level, the magnitude of testosterone suppression could not be entirely explained by the nature of the decline in plasma LH which fell much less (Rajfer et al., 1986) . These results support our finding that a decreased secretion of immunoreactive gonadotropins is not responsible for the suppression of estrogen production.
A review of the literature shows that there is no previous report of chronic GnRH treatment on pituitary LH pulses in women, although a marked decrease in the frequency and amplitude of LH pulses following the constant infusion of GnRH agonist has been reported in men (Bhasin et al., 1987) . In the present study, a pulsatile LH secretion observed in a pretreatment cycle disappeared in all patients examined, whose estrogen levels fell to the near-castrate level following chronic buserelin treatment.
It is believed that ovarian follicular development occurs with pulsatile gonadotropin secretion.
It is, therefore, likely that the absence of, or a marked decrease in, the frequency of LH pulses results in decreased estrogen production in women. A significant decrease in the pituitary response to GnRH during the treatment was demonstrated in the patients with endometriosis. However, the pulsatile frequency of LH is governed by hypothalamic influences (Knobil, 1980) . There is no evidence that GnRH agonist causes a direct ultrashort feedback on the hypothalamic GnRH pulse generator. The mechanism by which chronic GnRH treatment inhibits pulsatile gonadotropin secretion is not yet known. A marked decrease in the serum bioassayable LH concentration during chronic buserelin treatment suggests secretion of a molecularly altered LH species with diminished biological activity. Evans et al.(1984) provided evidence of molecular heterogeneity of circulating LH during GnRH agonist treatment.
The reduction in serum bioactive LH in the patients with endometriosis correlated with the reduction in serum E2 during buserelin administration. Similar data demonstrating a significant reduction in serum bioactive LH after GnRH agonist treatment have been reported in women with endometriosis and those with polycystic ovarian disease (Meldrum et al., 1984) . GnRH agonist may inhibit ovarian function in patients with endometriosis by multiple mechanisms. These include secretion of a molecularly altered LH with diminished biological activity. It may be speculated that buserelin treatment also decreased serum bioassayable FSH and consequently suppressed estrogen production in the patients with endometriosis.
Recent studies, however, have demonstrated that chronic GnRH agonist administration does not alter the qualitative characteristics of FSH in normal men (Pavlou et al., 1988) . In contrast, GnRH antagonists seem to have a unique ability to decrease the biological potency of FSH in normal men (Dahl et al., 1986) and normal women (Kessel et al., 1988) . To clarify whether chronic GnRH agonist treatment reduces serum bioactive FSH concentrations, a study in patients with endometriosis is under way in our laboratory.
One of the proposed mechanisms by which GnRH agonist suppresses estrogen production is a direct inhibition of ovarian steroid biosynthesis. In the present study, however, no direct inhibitory effect of GnRH agonist on ovarian estrogen biosynthesis was observed, since all the patients examined retained the ability to produce ovarian estrogen during chronic buserelin treatment.
Direct inhibitory effects of GnRH agonists on ovarian steroidogenesis have been demonstrated in rodent models (Hsueh and Erickson, 1979) . In a study with cultured human granulosa cells, GnRH agonist was also found to inhibit the secretion of progesterone in a dose-dependent manner (Tureck et al., 1982) . However, an ovarian site of action of GnRH agonist in the inhibition of gonadal function is less likely to be important in women, since GnRH receptors are not detectable in human ovaries (Clayton and Huhtaniemi, 1982) .
Several studies have failed to demonstrate that GnRH or GnRH agonist has an effect on human luteal cells in vitro (Casper et al., 1984) . The intratesticular steroid concentration and the enzymatic activity were significantly reduced in GnRH agonist-treated men, whereas the addition of human chorionic gonadotropin reversed these inhibition due to GnRH agonist (Rajfer et al., 1987) . These results also suggest that the inhibitory effect of GnRH agonist does not act directly on the testis but is mediated via the pituitary gland. Our conclusions regarding the ability to produce ovarian estrogen during GnRH agonist treatment are based on data obtained from only 4 cases. Nevertheless, a similar ovarian response to hMG load between before and during the treatment was sufficient to allow us to conclude that GnRH agonist does not have a direct inhibitory effect on ovarian steroidogenesis.
The most probable mechanism of action of GnRH agonist-induced resorption of endometriosis is estrogen deprivation and subsequent atrophy.
GnRH agonist may inhibit ovarian estrogen production in patients with endometriosis by multiple mechanisms. Indeed, a variety of:theories have been proposed to explain the GnRH agonist suppression of estrogen production in women. Based on the results obtained in the present study, however, it is strongly suggested that GnRH agonist suppression of estrogen production in patients with endometriosis is through both suppression of the secretion of bioactive LH and reduction of the LH pulse, but not through the suppression of immunoreactive gonadotropins and direct inhibition of ovarian estrogen biosynthesis.
